Addex Therapeutics annual revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Addex Therapeutics Revenue Growth & History (ADXN)
Addex Therapeutics reported CHF29,972 in revenue for fiscal 2025, a decrease of 92.69% from the previous fiscal year.
View full Addex Therapeutics company overviewAddex Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | CHF29,972 | −CHF380,070 | −92.69% |
| 2024 | 2024-12-31 | CHF410,042 | −CHF1.2M | −74.64% |
| 2023 | 2023-12-31 | CHF1.6M | CHF172,229 | +11.92% |
| 2022 | 2022-12-31 | CHF1.4M | −CHF1.7M | −54.18% |
| 2021 | 2021-12-31 | CHF3.2M | −CHF725,838 | −18.71% |
| 2020 | 2020-12-31 | CHF3.9M | CHF1.0M | +36.89% |
| 2019 | 2019-12-31 | CHF2.8M | −CHF3.9M | −57.72% |
| 2018 | 2018-12-31 | CHF6.7M | CHF6.2M | +1240.82% |
| 2017 | 2017-12-31 | CHF499,894 | — | — |
Addex Therapeutics quarterly revenue
Q2.21
Q2.22
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | CHF0 | CHF0 | — |
| Q4 2025 | 2025-12-31 | CHF248 | — | — |
| Q3 2025 | 2025-09-30 | CHF29,724 | — | — |
| Q2 2025 | 2025-06-30 | CHF36,375 | −CHF78,902 | −68.45% |
| Q1 2025 | 2025-03-31 | CHF0 | — | — |
| Q2 2024 | 2024-06-30 | CHF115,277 | −CHF516,700 | −81.76% |
| Q2 2023 | 2023-06-30 | CHF631,977 | CHF445,534 | +238.97% |
| Q2 2022 | 2022-06-30 | CHF186,443 | −CHF885,437 | −82.61% |
| Q2 2021 | 2021-06-30 | CHF1.1M | — | — |
Addex Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue declined from CHF3.9M to CHF29,972, a compound annual decline of 62.19%. Addex Therapeutics's latest reported quarter, Q1 2026, generated CHF0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Addex Therapeutics source filings ↗Community posts
Addex reports limited cash as half-year loss reaches CHF3.46 million
Addex Therapeutics ($ADXN) reported a first-half net loss of CHF3.46 million, compared with CHF3.31 million a year earlier. Its operating loss narrowed to CHF1.13 million, but the share of losses from associates increased to CHF2.33 million ...
